Brief: Senseonics Q2 EPS USD -0.02

Senseonics Holdings

06/08/2025 21:05

Overview

Senseonics Q2 revenue grows 37% yr/yr to $6.6 mln, driven by U.S. patient growth

Net loss narrows to $14.5 mln, aided by improved gross profit margins

Co raises $77.8 mln to support Eversense 365 launch and pipeline development

Outlook

Senseonics expects 2025 revenue of $34-38 mln

Company projects 2025 gross margins of 32.5%-37.5%

Senseonics anticipates cash use of $60 mln in 2025

Revenue expected to be weighted to Q4 due to reorder dynamics

Result Drivers

U.S. PATIENT GROWTH - 79% increase in new patient starts in the U.S. drives revenue growth

DTC ADVERTISING - Expanded direct-to-consumer campaign boosts leads by 50%

GROSS PROFIT MARGINS - Improved margins on 365-day product and one-time tax gain enhance profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.02
Q2 Net Income
-$14.50 mln
Q2 Gross Profit
$3.12 mln
Q2 Operating Income
-$14.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Senseonics Holdings Inc is $1.33, about 61.8% above its August 5 closing price of $0.51

Press Release: ID:nGNX5JVQQ8

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)